// App-Quantinova.ai

TPS6109 : A phase I study of metformin in combination with cisplatin and radiation in locally advanced head and neck squamous cell carcinoma.

Researchers

Presenter

  • Trisha Michel Wise-Draper

Principal Investigators

  • Vinita Takiar

  • Michelle Lynn Mierzwa

  • Bradley Joseph Huth

  • Kevin P. Redmond

  • William Barrett

  • Julianne Qualtieri

  • Changchun Xie

  • John Charles Morris

  • J. Silvio Gutkind

  • Nooshin Hashemi Sadraei

Medical Centers

  • University of Cincinnati Cancer Institute, Cincinnati, OH

  • University of Cincinnati, Cincinnati, OH

  • University of Michigan, Ann Arbor, MI

  • University Of Cincinnati Barrett Cancer Ctr, Cincinnati, OH

  • University Hospital, Cincinnati, OH

  • University of Cincinnati Medical Center Biostatistics, Cincinnati, OH

  • Division of Hematology-Oncology, Department of Medicine, University of Cincinnati Cancer Institute, Cincinnati, OH

  • University of California-San Diego, San Diego, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • Programmed cell death protein 1

  • Cluster of differentiation 8A

  • C-peptide

  • TNF Alpha Induced Protein 1

Drug/Treatment

  • Cyanocobalamin

  • Metformin Hydrochloride

  • Cisplatin

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT02325401

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved